TC BioPharm Closes $6M Upsized Public Offering

TC BioPharm (Holdings) PLC, a biotechnology company based in Edinburgh, Scotland, has announced the successful closure of its public offering. The company, listed on NASDAQ under the ticker TCBP, focuses on developing allogeneic gamma-delta T cell therapies for cancer and other conditions. The recent public offering was increased to 6,000,000 American Depository Shares (ADSs) or pre-funded warrants, along with Series H warrants to purchase an equivalent amount of ADSs. Each ADS represents two hundred ordinary shares of TC BioPharm.

The combined public offering price was set at $1 per ADS or pre-funded warrant, with the Series H warrants priced at £0.76 per ADS. These warrants are exercisable immediately upon issuance and will expire one year from their issue date. The gross proceeds from this offering amount to $6 million, before subtracting the expenses related to the offering.

TC BioPharm intends to allocate the net proceeds from this offering towards several strategic areas. These include the upcoming clinical trial for relapse/refractory Acute Myeloid Leukemia (AML), enhancing market awareness, and covering ongoing operating expenses as well as working capital needs.

The securities were offered under a registration statement on Form F-1 (File No. 333-281613), which had been filed with and approved by the U.S. Securities and Exchange Commission (SEC) on August 28, 2024. An additional registration statement on Form F-1, filed under Rule 462(b), also became effective on the same date. The offering was conducted exclusively through a prospectus that is part of the effective registration statement. Interested parties can access electronic copies of the final prospectus on the SEC's website.

This announcement does not serve as an offer or solicitation to buy or sell any of the securities mentioned. It also does not imply that these securities can be traded in any state or jurisdiction where such activities have not been registered or qualified under the relevant securities laws.

TC BioPharm is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of gamma-delta T cell therapies, particularly for cancer treatment. The company has demonstrated human efficacy data for its treatments targeting acute myeloid leukemia. Gamma-delta T cells are unique immune cells that combine features of both the innate and adaptive immune systems, enabling them to distinguish between healthy and diseased tissues naturally.

As a pioneer in gamma-delta T cell therapies, TC BioPharm was the first to conduct phase II/pivotal clinical studies in oncology using this approach. Currently, the company is running two investigator-initiated clinical trials. These include a Phase 2b/3 pivotal trial for acute myeloid leukemia, utilizing the company’s proprietary allogeneic CryoTC technology. This technology allows TC BioPharm to provide frozen gamma-delta T cell products to clinics around the globe, thereby facilitating broader access to their innovative treatments.

TC BioPharm continues to lead the charge in the biopharmaceutical sector, focusing on groundbreaking treatments that harness the body's natural immune mechanisms. By advancing gamma-delta T cell therapies, the company aims to offer new hope for patients battling cancer, particularly those with challenging conditions like acute myeloid leukemia.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!